Biomaterial Database

A vaccine against Ebola: Problems and opportunities. 2015

Giovanni Rezza

a Department of Infectious, Parasitic, and Immunomediated Diseases; Istituto Superiore di Sanità ; Roma , Italy.

The unprecedented dimensions of the 2014 Ebola epidemic which ravaged 3 West African countries have challenged public health response capacity and urged the availability of safe and effective vaccines. In this context, vectored vaccines already tested in animal models have undergone phase 1 studies in human beings and are now ready for efficacy evaluation in large scale trials. Health care workers and other frontline caregivers are likely to be the target population for both vaccine trials and vaccination campaigns. However, methodological and ethical issues should be considered in plans concerning the conduction of clinical trials and the possible use of licensed vaccines against Ebola.

UI	MeSH Term	Description	Entries
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000354	Africa, Western	The geographical area of Africa comprising BENIN; BURKINA FASO; CABO VERDE, COTE D'IVOIRE (formerly Ivory Coast); GAMBIA; GHANA; GUINEA; GUINEA-BISSAU; LIBERIA; MALI; MAURITANIA; NIGER; NIGERIA; SENEGAL; SIERRA LEONE; and TOGO.	Africa, West,West Africa,Western Africa
D017321	Clinical Trials, Phase I as Topic	Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.	Clinical Trials, Phase I,Drug Evaluation, FDA Phase I,Evaluation Studies, FDA Phase I,Human Microdosing Trial,Phase 1 Clinical Trial,Phase I Clinical Trial,Phase I Clinical Trials,Clinical Trials, Phase 1,Drug Evaluation, FDA Phase 1,Drug Evaluation, FDA Phase I as Topic,Evaluation Studies, FDA Phase 1,Human Microdosing Trials,Microdosing Trials, Human,Phase 1 Clinical Trials,Microdosing Trial, Human,Trial, Human Microdosing,Trials, Human Microdosing
D046129	Ebola Vaccines	Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER.	Ebola Vaccine,Ebola Virus Vaccine,Ebola Virus Vaccines,Ebolavirus Vaccine,Ebolavirus Vaccines,Vaccine, Ebola,Vaccine, Ebola Virus,Vaccine, Ebolavirus,Vaccines, Ebola,Vaccines, Ebola Virus,Vaccines, Ebolavirus,Virus Vaccine, Ebola,Virus Vaccines, Ebola
D055808	Drug Discovery	The process of finding chemicals for potential therapeutic use.	Drug Prospecting,Discovery, Drug,Prospecting, Drug
D019142	Hemorrhagic Fever, Ebola	A highly fatal, acute hemorrhagic fever caused by EBOLAVIRUS.	Ebola Hemorrhagic Fever,Ebola Virus Disease,Ebolavirus Infection,Ebola Infection,Ebola Virus Infection,Ebolavirus Infections,Infection, Ebola,Infection, Ebola Virus,Infection, Ebolavirus,Infections, Ebolavirus,Virus Infection, Ebola